All In Biotech

Drug Trial Radar · NCT06265220

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Apr 3, 2024

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Artiva Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus. The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus. Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status. Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.

Conditions

  • Lupus Nephritis - WHO Class III
  • Lupus Nephritis - WHO Class IV
  • Refractory Systemic Lupus Erythematosus
  • SLE

Interventions

  • AB-101Drug

    NK Cell Therapy

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy

  • FludarabineDrug

    Lymphodepleting chemotherapy

  • RituximabDrug

    Anti-CD20 antibody therapy

  • ObinutuzumabDrug

    Anti-CD20 antibody therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events and Serious Adverse EventsTime frame: From the time of consent through 104 weeks after initiation of study treatment
  2. AB-101 Clinical ActivityTime frame: From the time of first dose through 104 weeks after initiation of study treatment

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Artiva Investigational Site Birmingham

    Birmingham, Alabama

  • Artiva Investigational Site Tucson

    Tucson, Arizona

  • Artiva Investigational Site San Diego

    San Diego, California

  • Artiva Investigational Site Aventura

    Aventura, Florida

  • Artiva Investigational Site Plantation

    Plantation, Florida

  • Artiva Investigational Site Iowa

    Iowa City, Iowa

  • Artiva Investigational Site Charlotte

    Charlotte, North Carolina

  • Artiva Investigational Site Mesquite

    Mesquite, Texas

  • Artiva Investigational Site Woodlands

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.